Chiusura precedente | 13,13 |
Aperto | 13,08 |
Denaro | 0,00 x N/D |
Lettera | 0,00 x N/D |
Min-Max giorno | 13,01 - 13,08 |
Intervallo di 52 settimane | 13,01 - 17,13 |
Volume | |
Media Volume | 1.118 |
Capitalizzazione | N/D |
Beta (5 anni mensile) | 0,54 |
Rapporto PE (ttm) | 0,24 |
EPS (ttm) | 0,54 |
Prossima data utili | N/D |
Rendimento e dividendo (futuro) | N/D (N/D) |
Data ex dividendo | N/D |
Stima target 1A | 17,61 |
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that Takeda (TSE:4502/NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in Japan for the approval of fruquintinib for the treatment of adult patients with previously
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) and Takeda (TSE:4502, NYSE:TAK) today announced that results